Immunohistochemical detection of follicle stimulating hormone receptor (FSHR) in neuroendocrine tumours by Pawlikowski, Marek et al.
268
Prace oryginalne/original PaPers
Endokrynologia Polska
DOI: 10.5603/EP.2013.0004
Tom/Volume 64; Numer/Number 4/2013
ISSN 0423–104X
Marek Pawlikowski M.D., Ph.D., Department of Immunoendocrinology, Chair of Endocrinology, Medical University of Lodz, Sterlinga St. 3, 
91–425 Łódź, Polska, tel. +48 42 664 43 89, e-mail: marek.pawlikowski@umed.lodz.pl
Immunohistochemical detection of follicle stimulating 
hormone receptor (FSHR) in neuroendocrine tumours
Immunohistochemiczna detekcja receptorów folitropiny (FSHR) w guzach 
neuroendokrynnych
Marek Pawlikowski1, Katarzyna Winczyk2, Henryk Stępień1
1Department of Immunoendocrinology, Chair of Endocrinology, Medical University of Lodz, Poland 
2Department of Neuroendocrinology, Chair of Laboratory Medicine, Medical University of Lodz, Poland
Abstract
Introduction: Follicle stimulating hormone receptors (FSHR) are well known to be expressed in gonads and in gonadal tumours. Recently, 
their incidence has also been revealed in endocrine non-gonadal tumours such as adrenal and pituitary tumours. Moreover, FSHR im-
munostaining has also been reported in endothelium of intra- and peritumoral blood vessels of a large series of cancers. The present 
paper reports on the incidence of FSHR in both tumoral cells and some intratumoral blood vessels of neuroendocrine tumours (NETs).
Material and methods: Sixteen NETs samples were taken from 14 patients. The tumour samples were immunostained using the antibody 
raised against 1-190 amino acid sequence from the human FSH-R and anti-Ki67 antibody.
Results: In all the samples examined, the majority of tumoral cells were immunostained with anti-FSHR antibody. Positive immunostaining 
concerned also the intratumoral blood vessels endothelia in a half of the examined samples. Immunopositive blood vessels were found 
more often in tumours with higher Ki-67 index.
Conclusion: FSHR expressed in NETs, if they are functional, may mediate the signals which can enhance further tumour growth. 
(Endokrynol Pol 2013; 64 (4): 268–271)
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Streszczenie
Wstęp: Wiadomo, że ekspresja receptorów folitropiny (FSHR) występuje w gonadach i wywodzących się z gonad nowotworach. Ostat-
nio wykazano ich obecność także w innych nowotworach endokrynnych, takich jak guzy nadnerczy i gruczolaki przysadki. Ponadto 
stwierdzono immunopozytywność dla FSHR w śródbłonkach około- i wewnątrzguzowych naczyń krwionośnych różnych nowotworów 
złośliwych. W obecnej pracy wykazano obecność FSHR zarówno w komórkach nowotworowych, jak i niektórych wewnątrz-guzowych 
naczyniach krwionośnych guzów neuroendokrynnych (NETs).
Materiał i metody: Zbadano 16 wycinków pobranych od 14 pacjentów z NETs. Odczyny immunohistochemiczne wykonano z użyciem 
przeciwciała skierowanego przeciw fragmentowi 1-190 ludzkiego FSHR oraz przeciwciała dla Ki-67. 
Wyniki: Dodatni odczyn z przeciwciałem anty-FSHR stwierdzono w cytoplazmie większości komórek badanych guzów. W połowie ba-
danych NETs odnotowano także immunopozytywność dla FSHR w śródbłonkach wewnątrzguzowych naczyń krwionośnych. Dodatni 
odczyn dla FSHR obserwowano częściej w naczyniach krwionośnych nowotworów z wyższym indeksem Ki-67. 
Wnioski: Ektopowe FSHR, jeśli są one aktywne, mogą przekazywać sygnały nasilające dalszy wzrost NETs. (Endokrynol Pol 2013; 64 (4): 268–271)
Słowa kluczowe: receptory FSH, guzy neuroendokrynne, śródbłonek naczyniowy
Introduction
Follicle stimulating hormone receptors (FSHR) are well 
known to be expressed in gonads and in gonadal tumours 
[1]. However, their incidence was also recently revealed in 
numerous non-gonadal tumours. Radu et al. [2] found the 
expression of FSHR in endothelia of intra- and peritumoral 
blood vessels in a large series of non-gonadal cancers 
(prostate, breast, colon, pancreas, bladder, kidney, lung, 
liver and stomach). The quoted authors claim that FSHR 
incidence is specific for tumoral and peritumoral blood 
vessels since they found them neither in endothelia of 
non-tumoral vessels nor in tumoral cells. In our earlier 
study, we showed that FSHR could be detected immu-
nohistochemically in both endothelia and tumoral cells 
in non-gonadal endocrine tumours: pituitary adenomas, 
adrenocortical tumours and pheochromocytomas [3]. 
Recently the presence of FSHR has been also reported in 
pancreatic neuroendocrine tumours [4]. Simultaneously, 
a similar preliminary observation concerning NETs of 
different origin, was done by us [5]. 
The present paper reports on the incidence of FSHR 
in both tumoral cells and some intratumoral blood ves-
sels of neuroendocrine tumours. 
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Figure 1. Intestinal ‘carcinoid’ in 32 year-old woman immunostained with anti-FSHR antibody. Positive immunostaining of tumoral 
cells can be seen. Original magnification 400 ×
Rycina 1. Jelitowy „carcinoid” u 32-letniej kobiety barwiony z użyciem przeciwciała anty-FSHR. Widoczny pozytywny odczyn 
w komórkach guza. Powiększenie oryginalne 400 ×
Figure 2. The same tumour as in Figure 1 stained without anti-FSHR antibody. Original magnification 400 ×
Rycina 2.Ten sam guz co na rycinie 1 barwiony z pominięciem przeciwciała anty-FSHR. Powiększenie oryginalne 400 ×
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Figure 4. Intestinal ‘carcinoid’ in 62 year-old man. Positive immunostaining with anti-FSHR antibody in both tumoral cells and blood 
vessel (arrow) can be seen. Original magnification 400 ×
Rycina 4. Jelitowy „carcinoid” u 62-letniego mężczyzny barwiony z użyciem przeciwciała anty-FSHR. Widoczny pozytywny odczyn 
zarówno w komórkach guza, jak i w naczyniu krwionośnym (strzałka). Powiększenie oryginalne 400 ×
Figure 3. The same tumour as in Figure 1. Negative immunostaining of a blood vessel wall (arrows). Original magnification 400 ×
Rycina 3. Ten sam guz co na rycinie1. Negatywny odczyn w ścianie naczynia krwionośnego (strzałki). Powiększenie oryginalne 400 ×
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Material and methods
Sixteen NETs samples were taken from 14 patients. The 
samples concerned five bronchial ‘carcinoids’, seven 
intestinal ‘carcinoids’, three metastases to the liver 
and one neuroendocrine pancreatic cancer. Paraffin 
sections of the tumour samples were immunostained 
using the rabbit polyclonal antibody raised against 
1-190 amino acid sequence from the human FSH-R 
(sc-13935) purchased from Santa Cruz Biotechnology 
Inc. (Santa Cruz Biotechnology, CA, USA), applied 
in a working dilution of 1:100. Additionally, the sec-
tions were immunostained with anti-Ki-67 (MIB-1) 
monoclonal antibody (Dako Cytomation, Glostrup, 
Denmark). The visualisation of the primary antibod-
ies was done by means either of the REAL EnVision 
Detection System (FSHR) or the StreptABComplex/ 
/HRP Duet (Ki 67), both purchased from Dako Cytoma-
tion. The intensity of immunostaining in the tumoral 
cell cytoplasm was scored semiquantitatively using a 
descriptive scale: negative staining (score = 0), weak 
staining (score = 1), moderate staining (score = 2) and 
strong staining (score = 3). For a negative control, the 
primary antibody was omitted in the immunostain-
ing procedure. For a positive control, a sample of the 
human testis was used.
This study was approved by the Local Bioethical 
Committee, decision number RNN/537/11/KB dated 
14 June, 2011.
Results
In all the samples examined, the majority of tumoral cells 
were immunostained with anti-FSHR antibody (Fig. 1 and 
2). Positive immunostaining concerned also the intratu-
moral blood vessels endothelia in 8/16 examined samples 
(Fig. 3 and 4). When we compared NETs samples accord-
ing to Ki-67 values, there was no evident difference in 
FSHR immunostaining scores in tumoral cells. The mean 
score calculated in NET samples with Ki-67 index ≥ 2% was 
1.8 ± 0.2 (means ± SEM) and in the samples with Ki-67 < 
2% it was 1.5 ± 0.3 (means ± SEM). On the other hand, 
immunopositive blood vessels were found more often in 
the tumours with higher Ki-67 index (5/6 with Ki-67 ≥ 2% 
and 2/9 with Ki-67 < 2%).
Discussion
The observations presented above corroborate the data 
of Sardella et al. [4] showing that FSHR are expressed 
in tumoral cells of NETs. The quoted authors showed 
that FSHR co-localise with chromogranin A, a marker 
of tumoral cells, but not with von Willebrand’s factor, 
which is a marker of vascular endothelia. However, 
in contrast to the cited data, our finding shows that 
FSHR were localised not only in the tumoral cells, 
but in some cases in blood vessels as well. This ob-
servation, in turn, is in agreement with the earlier 
data of Radu et al. [2] who demonstrated the FSHR 
immunopositivity of vascular endothelia in the intra- 
and peritumoral blood vessels of different cancers. 
However, it must be underlined that the endothelial 
immunostaining in NETs in our study occurred only 
in a half of the samples examined by us, and is rather 
rare in tumours with lower grade of differentiation. 
We did not observe the differences depending on the 
origin of NETs, however, our material was too small 
to allow a definitive conclusion. 
The question arises whether the ectopic expres-
sion of FSHR in NETs have any consequences for the 
clinical outcome of the tumour. The functionality of 
these receptors remains unknown and needs further 
study. It is known that the ovary stimulation of FSHR 
by FSH leads to the enhanced proliferation of granu-
losa cells, increased secretion of vascular endothelial 
growth factor (VEGF), and increased angiogenesis [6]. 
A similar observation was made with ovarian cancer 
cells SK-OV-3 [6]. FSH also inhibits ovarian cancer cell 
apoptosis by up-regulating survivin and downregulat-
ing programmed cell death gene 6 (PDCD6) and death 
receptor 5 (DR5) [7, 8].
Summing up, FSHR, if they are functional, may medi-
ate the signals which can enhance further tumour growth.
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